Skip to content

A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002151
Enrollment
200
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Drug Therapy, Combination, AIDS-Related Complex, Zidovudine, MDL 28574

Brief summary

To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection. To examine the demographic effects on population pharmacokinetics and pharmacodynamics of MDL 28,574A alone and in combination with AZT.

Interventions

Sponsors

Hoechst Marion Roussel
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Concurrent Medication: Allowed: * Prior antiretroviral agents for up to 6 months per agent. Patients must have: * HIV infection. * Asymptomatic or mildly symptomatic. * CD4 count 301 - 500 cells/mm3.

Exclusion criteria

Co-existing Condition: Patients with the following condition are excluded: Unable or unwilling to comply with study procedures. Concurrent Medication: Excluded: * Chemoprophylactic therapy for mycobacterial infection. * Any nonstudy prescription medications without approval of investigator. Patients with the following prior conditions are excluded: * History of grade 3 or 4 toxicity to \<= 600 mg/day AZT. * History of intolerance to lactose. * Chronic diarrhea within 6 months prior to study entry. * Unexplained intermittent or chronic fever, defined as temperature \>= 38.5 C for any 7 days within the 30 days prior to study entry. Prior Medication: Excluded: * Antiretroviral therapy within 2 weeks prior to study entry. * Prior HIV vaccines. * Biological response modifiers within 30 days prior to study entry. * Prior foscarnet. * Any investigational drug with a washout \< 5 half-lives prior to study entry. * Any medications known to alter renal, hepatic, or hematologic / immunologic function (such as barbiturates, phenothiazines, cimetidine, immunomodulators, etc.) within 14 days prior to study entry. Recent history of alcohol and/or drug abuse.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026